Zhang J - Search Results

1

Recent advances and impending challenges for the radiopharmaceutical sciences in oncology.

Lapi SE, Scott PJH, Scott AM, Windhorst AD, Zeglis BM, Abdel-Wahab M, Baum RP, Buatti JM, Giammarile F, Kiess AP, Jalilian A, Knoll P, Korde A, Kunikowska J, Lee ST, Paez D, Urbain JL, Zhang J, Lewis JS. Lapi SE, et al. Among authors: zhang j. Lancet Oncol. 2024 Jun;25(6):e236-e249. doi: 10.1016/S1470-2045(24)00030-5. Lancet Oncol. 2024. PMID: 38821098 Review.

2

Theranostics of prostate cancer: from molecular imaging to precision molecular radiotherapy targeting the prostate specific membrane antigen.

Kulkarni HR, Singh A, Langbein T, Schuchardt C, Mueller D, Zhang J, Lehmann C, Baum RP. Kulkarni HR, et al. Among authors: zhang j. Br J Radiol. 2018 Nov;91(1091):20180308. doi: 10.1259/bjr.20180308. Epub 2018 Jun 1. Br J Radiol. 2018. PMID: 29762048 Free PMC article. Review.

3

Ten-Year Survival After Peptide Receptor Radionuclide Therapy of a Metastatic Well-differentiated G3 Pancreatic Neuroendocrine Neoplasm.

Zhang J, Kulkarni HR, Singh A, Baum RP. Zhang J, et al. Clin Nucl Med. 2018 Sep;43(9):676-678. doi: 10.1097/RLU.0000000000002186. Clin Nucl Med. 2018. PMID: 30080185

4

Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients.

Zhang J, Kulkarni HR, Singh A, Niepsch K, Müller D, Baum RP. Zhang J, et al. J Nucl Med. 2019 Mar;60(3):377-385. doi: 10.2967/jnumed.118.215848. Epub 2018 Aug 16. J Nucl Med. 2019. PMID: 30115686 Free article.

5

Pregnancy and Delivery After PRRT Without Sequelae.

Zhang J, Kulkarni HR, Lehmann C, Singh A, Baum RP. Zhang J, et al. Clin Nucl Med. 2018 Nov;43(11):842-845. doi: 10.1097/RLU.0000000000002267. Clin Nucl Med. 2018. PMID: 30179916

6

Delayed Response (Partial Remission) 3 Years After Peptide Receptor Radionuclide Therapy in a Patient Participating in the NETTER-1 Trial.

Zhang J, Kulkarni HR, Singh A, Baum RP. Zhang J, et al. Clin Nucl Med. 2019 Mar;44(3):223-226. doi: 10.1097/RLU.0000000000002456. Clin Nucl Med. 2019. PMID: 30672759

7

¹⁷⁷Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients with a Single Functioning Kidney.

Zhang J, Kulkarni HR, Singh A, Schuchardt C, Niepsch K, Langbein T, Baum RP. Zhang J, et al. J Nucl Med. 2019 Nov;60(11):1579-1586. doi: 10.2967/jnumed.118.223149. Epub 2019 Mar 8. J Nucl Med. 2019. PMID: 30850499 Free article.

8

Prostate-Specific Membrane Antigen Accumulation in Lower Extremity Lymphedema.

Zhang J, Kulkarni HR, Singh A, Baum RP. Zhang J, et al. Clin Nucl Med. 2019 Jun;44(6):501-503. doi: 10.1097/RLU.0000000000002552. Clin Nucl Med. 2019. PMID: 30932981

9

Complete Regression of Lung Metastases in a Patient With Metastatic Castration-Resistant Prostate Cancer Using 177Lu-PSMA Radioligand Therapy.

Zhang J, Kulkarni HR, Singh A, Baum RP. Zhang J, et al. Clin Nucl Med. 2020 Jan;45(1):e48-e50. doi: 10.1097/RLU.0000000000002655. Clin Nucl Med. 2020. PMID: 31162261

10

From Bench to Bedside-The Bad Berka Experience With First-in-Human Studies.

Zhang J, Singh A, Kulkarni HR, Schuchardt C, Müller D, Wester HJ, Maina T, Rösch F, van der Meulen NP, Müller C, Mäcke H, Baum RP. Zhang J, et al. Semin Nucl Med. 2019 Sep;49(5):422-437. doi: 10.1053/j.semnuclmed.2019.06.002. Epub 2019 Jul 6. Semin Nucl Med. 2019. PMID: 31470935 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

178,315 results

Search Page

Filters